Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  JAMA Oncology

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2014.218PMID 26182309PMCID PMC4520535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

  2014cited by this paper
• Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

  2014cited by this paper
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

  2013cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

  2010cited by this paper
• The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

  2010cited by this paper
• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  2010cited by this paper
• Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

  2002cited by this paper
• Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

  2001cited by this paper
• Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.

  2000cited by this paper
• Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1

  2000cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• Clinical staging of chronic lymphocytic leukemia.

  1977cited by this paper
• Clinical staging of chronic lymphocytic leukemia.

  1975cited by this paper

• Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies.

  2026cites this paper
• Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways

  2026cites this paper
• Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation.

  2026cites this paper
• Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives.

  2026cites this paper
• Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

  2026cites this paper
• When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia

  2026cites this paper
• The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia

  2025cites this paper
• Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi.

  2025cites this paper
• Functional proteoform group deconvolution reveals a broader spectrum of ibrutinib off-targets

  2025cites this paper
• Real-world use of BTK inhibitors for chronic lymphocytic leukemia in Japan: A retrospective observational database study

  2025cites this paper
• Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors

  2025cites this paper
• Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures.

  2025cites this paper
• Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

  2025cites this paper
• Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression

  2025cites this paper
• Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

  2025cites this paper
• Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop

  2025cites this paper
• Piperidine-catalyzed synthesis of (E)-2-cyanoacrylamides: crystallographic, antiproliferative, and docking studies

  2025cites this paper
• Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment

  2025cites this paper
• Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center

  2025cites this paper
• Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies

  2025cites this paper
• A Case‐Driven Multi‐Omics Analysis for Longitudinal Ibrutinib Response Evaluation of Patients With Chronic Lymphocytic Leukemia

  2025cites this paper
• Updates on the Treatment of Richter’s Syndrome, Including Novel Combination Approaches

  2025cites this paper
• Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

  2025cites this paper
• Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors – systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia

  2025cites this paper
• BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.

  2025cites this paper
• Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy

  2025cites this paper
• Resistance to Bruton Tyrosine Kinase Inhibitors.

  2025cites this paper
• Chimeric Antigen Receptor T-cell Therapy for Richter Transformation: A CIBMTR analysis.

  2025cites this paper
• Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia.

  2025cites this paper
• Novel Mechanisms of Resistance in CLL: Variant BTK Mutations in Second-Generation and Noncovalent BTK Inhibitors.

  2025cites this paper
• Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges

  2025cites this paper
• Harnessing p53 for targeted cancer therapy: new advances and future directions

  2025cites this paper
• Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia

  2024cites this paper
• Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib

  2024cites this paper
• Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

  2024cites this paper
• Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia.

  2024cites this paper
• Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

  2024cites this paper
• A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia

  2024cites this paper
• Targeting of human cancer stem cells predicts efficacy and toxicity of FDA-approved oncology drugs.

  2024cites this paper
• Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management

  2024cites this paper
• PET/CT in leukemia: utility and future directions

  2024cites this paper
• Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain‐of‐function variations

  2024influential citation
• Prognostication in chronic lymphocytic leukemia.

  2024cites this paper
• The molecular map of CLL and Richter's syndrome.

  2024cites this paper
• Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study

  2024cites this paper
• Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

  2024cites this paper
• Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

  2024cites this paper
• Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

  2024cites this paper
• Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US

  2024cites this paper
• Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era

  2024cites this paper
• BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: case report and literature review.

  2024cites this paper
• JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL

  2024cites this paper
• Innovative design and potential applications of covalent strategy in drug discovery.

  2024cites this paper
• FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

  2024cites this paper
• Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies

  2024cites this paper
• Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

  2024cites this paper
• Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia

  2024cites this paper
• Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib

  2024cites this paper
• Aberrantly Expressed Mitochondrial Lipid Kinase, AGK Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy.

  2024cites this paper
• Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities

  2024cites this paper
• Passengers, drivers, and “goners”

  2024cites this paper
• Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures

  2024cites this paper
• BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

  2024cites this paper
• Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study

  2024cites this paper
• Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

  2023cites this paper
• Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

  2023cites this paper
• Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study

  2023cites this paper
• Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)

  2023cites this paper
• Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies

  2023cites this paper
• Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes

  2023cites this paper
• Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib

  2023cites this paper
• Richter's transformation: Transforming the clinical landscape.

  2023cites this paper
• Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

  2023cites this paper
• Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia

  2023cites this paper
• Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia

  2023cites this paper
• Zanubrutinib for the treatment of chronic lymphocytic leukemia

  2023cites this paper
• Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers

  2023cites this paper
• Evaluation of the relative allelic load of mutations of resistance to ibrutinib in the BTK gene by allele-specific PCR in patients with progression of CLL

  2023cites this paper
• Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma

  2023cites this paper
• Richter Transformation of Chronic Lymphocytic Leukemia—Are We Making Progress?

  2023cites this paper
• Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors

  2023cites this paper
• First line therapy of CLL

  2023cites this paper
• Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

  2023cites this paper
• Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

  2023cites this paper
• BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib

  2023influential citation
• B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

  2023cites this paper
• Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

  2023cites this paper
• Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

  2023cites this paper
• Outcomes of CD19-directed Chimeric Antigen Receptor T-cell Therapy for Transformed Non-follicular Lymphoma.

  2023cites this paper
• Review of the Efficacy of Bruton Tyrosine Kinase (BTK) Inhibitors on Primary Central Nervous System Lymphoma

  2023cites this paper
• BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

  2023cites this paper
• A systematic review evaluating the efficacy of autologous hematopoietic transplantation for diffuse large B cell lymphoma-type Richter syndrome

  2023cites this paper
• Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia

  2023cites this paper
• Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

  2023cites this paper
• 加速期慢性淋巴细胞白血病患者的临床和分子生物学特征分析

  2023cites this paper
• Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation

  2023cites this paper
• Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors

  2023cites this paper
• SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia.

  2023cites this paper
• A Rare Entity of Accelerated Chronic Lymphocytic Leukemia: A Report of Two Cases and Review of Literature

  2023cites this paper